These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 27262369)

  • 1. Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma.
    Sonpavde G; Pond GR; Di Lorenzo G; Buonerba C; Rozzi A; Lanzetta G; Necchi A; Giannatempo P; Raggi D; Matsumoto K; Choueiri TK; Mullane S; Niegisch G; Albers P; Lee JL; Kitamura H; Kume H; Bellmunt J
    Clin Genitourin Cancer; 2016 Dec; 14(6):494-498. PubMed ID: 27262369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
    Sonpavde G; Pond GR; Choueiri TK; Mullane S; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Buonerba C; Rozzi A; Matsumoto K; Lee JL; Kitamura H; Kume H; Bellmunt J
    Eur Urol; 2016 Apr; 69(4):634-641. PubMed ID: 26264159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
    Necchi A; Sonpavde G; Lo Vullo S; Giardiello D; Bamias A; Crabb SJ; Harshman LC; Bellmunt J; De Giorgi U; Sternberg CN; Cerbone L; Ladoire S; Wong YN; Yu EY; Chowdhury S; Niegisch G; Srinivas S; Vaishampayan UN; Pal SK; Agarwal N; Alva A; Baniel J; Golshayan AR; Morales-Barrera R; Bowles DW; Milowsky MI; Theodore C; Berthold DR; Daugaard G; Sridhar SS; Powles T; Rosenberg JE; Galsky MD; Mariani L;
    Eur Urol; 2017 Feb; 71(2):281-289. PubMed ID: 27726966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design.
    Pond GR; Bellmunt J; Rosenberg JE; Bajorin DF; Regazzi AM; Choueiri TK; Qu AQ; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Fougeray R; Wong YN; Sridhar SS; Ko YJ; Milowsky MI; Galsky MD; Sonpavde G
    Clin Genitourin Cancer; 2015 Feb; 13(1):71-9. PubMed ID: 24993933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cervical non-squamous carcinoma: an effective combination chemotherapy of taxane, anthracycline and platinum for advanced or recurrent cases.
    Kimura T; Miyatake T; Ueda Y; Ohta Y; Enomoto T; Kimura T; Kamiura S
    Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):200-4. PubMed ID: 22770633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.
    Sonpavde G; Pond GR; Rosenberg JE; Bajorin DF; Regazzi AM; Choueiri TK; Qu AQ; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Fougeray R; Dreicer R; Chen YH; Wong YN; Sridhar SS; Ko YJ; Milowsky MI; Galsky MD; Bellmunt J
    Clin Genitourin Cancer; 2015 Apr; 13(2):185-92. PubMed ID: 25458370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
    Salah S; Lee JL; Rozzi A; Kitamura H; Matsumoto K; Srinivas S; Morales-Barrera R; Carles J; Al-Wardat R; Al-Rabi K; Maakoseh M
    Clin Genitourin Cancer; 2016 Jun; 14(3):255-60. PubMed ID: 26552764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).
    Passalacqua R; Lazzarelli S; Donini M; Montironi R; Tambaro R; De Giorgi U; Pignata S; Palumbo R; Ceresoli GL; Del Conte G; Tonini G; Morelli F; Nolè F; Panni S; Rondini E; Guida A; Zucali PA; Doni L; Iezzi E; Caminiti C
    BMC Cancer; 2017 Jul; 17(1):493. PubMed ID: 28724419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
    Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
    Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
    Vaishampayan UN; Faulkner JR; Small EJ; Redman BG; Keiser WL; Petrylak DP; Crawford ED
    Cancer; 2005 Oct; 104(8):1627-32. PubMed ID: 16138364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of metastatic urothelial carcinoma treated by systemic chemotherapy: Prognostic factors based on real-world clinical practice in Japan.
    Abe T; Ishizaki J; Kikuchi H; Minami K; Matsumoto R; Harabayashi T; Sazawa A; Mochizuki T; Chiba S; Akino T; Murakumo M; Miyajima N; Tsuchiya K; Maruyama S; Murai S; Shinohara N
    Urol Oncol; 2017 Feb; 35(2):38.e1-38.e8. PubMed ID: 27693091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
    Pond GR; Bellmunt J; Fougeray R; Choueiri TK; Qu AQ; Niegisch G; Albers P; Di Lorenzo G; Salhi Y; Galsky MD; Agarwal N; Necchi A; Sonpavde G
    Clin Genitourin Cancer; 2013 Dec; 11(4):495-500. PubMed ID: 23800847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
    Galsky MD; Seng S; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
    Clin Genitourin Cancer; 2011 Sep; 9(1):27-30. PubMed ID: 21700509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.
    Necchi A; Lo Vullo S; Raggi D; Gloghini A; Giannatempo P; Colecchia M; Mariani L
    Eur Urol Focus; 2019 Sep; 5(5):853-856. PubMed ID: 29525380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world outcomes in locally advanced or metastatic urothelial carcinoma following platinum and PD-1/L1 inhibitor therapy.
    Hepp Z; Shah SN; Liang SY; Tan K; Balakrishna S
    Future Oncol; 2021 Nov; 17(32):4343-4353. PubMed ID: 34350778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study.
    Di Lorenzo G; Buonerba C; Bellelli T; Romano C; Montanaro V; Ferro M; Benincasa A; Ribera D; Lucarelli G; De Cobelli O; Sonpavde G; De Placido S
    Medicine (Baltimore); 2015 Dec; 94(51):e2297. PubMed ID: 26705213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.
    Jo JC; Lee JL; Ryu MH; Sym SJ; Lee SS; Chang HM; Kim TW; Lee JS; Kang YK
    Jpn J Clin Oncol; 2007 Dec; 37(12):936-41. PubMed ID: 18211985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage treatment with low-dose weekly paclitaxel in elderly or poor performance status patients with metastatic urothelial carcinoma.
    Han JJ; Kim YJ; Kim JW; Chang H; Lee JO; Lee KW; Jeong CW; Kim JH; Hong SK; Bang SM; Byun SS; Lee SE; Lee JS
    Tumori; 2014; 100(4):439-45. PubMed ID: 25296594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.
    Fukushima H; Kataoka M; Nakanishi Y; Sakamoto K; Takemura K; Suzuki H; Ito M; Tobisu KI; Fujii Y; Koga F
    Urol Oncol; 2018 Apr; 36(4):156.e9-156.e16. PubMed ID: 29051030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.
    Raggi D; Miceli R; Sonpavde G; Giannatempo P; Mariani L; Galsky MD; Bellmunt J; Necchi A
    Ann Oncol; 2016 Jan; 27(1):49-61. PubMed ID: 26487582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.